Figure 1From: Durable responses and reversible toxicity of high-dose interleukin-2 treatment of melanoma and renal cancer in a Community Hospital Biotherapy Program Kaplan-Meier (product limit) survival for melanoma (A) and RCC (B). Survival by best response as assessed by the treating physician in melanoma (C) and RCC (D).Back to article page